Trademark Overview
On Wednesday, February 28, 2024, a trademark application was filed for SMARXT with the United States Patent and Trademark Office. The USPTO has given the SMARXT trademark a serial number of 98426370. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, October 22, 2024. This trademark is owned by Immix Biopharma, Inc.. The SMARXT trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; pharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical compositions for the treatment of cancer; pharmaceutical drugs for the treatment of cancer; pharmaceutical preparations for human use for the treatment of cancer; pharmaceutical preparations and substances for the treatment of treatment-resistant cancers biological preparations for the treatment of cancer; biological preparations for medical purposes for the treatment of cancer; medical preparations for the treatment of cancer; medicinal preparations and substances for the treatment of cancer; medicines for human purposes for the treatment of cancer; injectable pharmaceuticals for the treatment of cancer; compounds for treating resistant cancers; pharmaceutical preparations and substances for use in oncology; pharmaceutical prepa...
scientific research in the field of oncology; scientific research in the field of immuo-dysregulated diseases; development of pharmaceutical preparations and medicines for the treatment of cancer; development of pharmaceutical preparations and medicines for the treatment of immuno-dysregulated diseases; clinical research in the field of oncology; clinical research in the field of immuo-dysregulated diseases; research and development services in the field of anti-cancer preparations; research and development services in the field of preparations for treating immuno-dysregulated diseases; design, engineering, research, development and testing services in the field of oncology; design, engineering, research, development and testing services in the field of immuno-dysregulated diseases; providing information regarding medical research relating to oncology; providing information regarding medical research relating to immuno-dysregulated diseases
